Captopril Versus Atenolol to Prevent Expansion Rate of Thoracic Aortic Aneurysms: Rationale and Design

References

• Sampson UK , NormanPE, FowkesFGet al. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Glob. Heart., 9(1), 171–180 (2014).
   PubMedGoogle Scholar
• Erbel R , AboyansV, BoileauCet al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases. Eur. Heart J., 35(41), 2873–2926 (2014).
   PubMed Web of Science ®Google Scholar
• Hackam DG , ThiruchelvamD, RedelmeierDA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case–control study. Lancet, 368(9536), 659–665 (2006).
   PubMed Web of Science ®Google Scholar
• Laupacis A , BarberG, HajjarGet al. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J. Vasc. Surg., 35(1), 72–79 (2002).
   PubMed Web of Science ®Google Scholar
• Cheung K , BoodhwaniM, ChanKL, BeauchesneL, DickA, CoutinhoT. Thoracic aortic aneurysm growth: role of sex and aneurysm etiology. J. Am. Heart Assoc., 6(2), e003792 (2017).
   PubMed Web of Science ®Google Scholar
• Landenhed M , EngströmG, GottsäterAet al. Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study. J. Am. Heart Assoc., 4(1), e001513 (2015).
   PubMed Web of Science ®Google Scholar
• Liao SL , ElmariahS, vander Zee S, SealoveBA, FusterV. Does medical therapy for thoracic aortic aneurysms really work? Are β-blockers truly indicated? CON. Cardiol. Clin., 28(2), 261–269 (2010)
   PubMed Web of Science ®Google Scholar
• Elefteriades JA . Does medical therapy for thoracic aortic aneurysms really work? Are β-blockers truly indicated? PRO. Cardiol. Clin., 28(2), 255–260 (2010).
   PubMed Web of Science ®Google Scholar
• Danyi P , ElefteriadesJA, JovinIS. Medical therapy of thoracic aortic aneurysms: are we there yet?Circulation, 124(13), 1469–1476 (2011)
   PubMed Web of Science ®Google Scholar
• Shores J , BergerKR, MurphyEA, PyeritzRE. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan’s syndrome. N. Engl. J. Med., 330(19), 1335–1341 (1994).
   PubMed Web of Science ®Google Scholar
• Mullen M , JinXY, ChildAet al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet, 394(10216), 2263–2270 (2019).
   PubMed Web of Science ®Google Scholar
• Forteza A , EvangelistaA, SánchezVet al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur. Heart J., 37(12), 978–985 (2016).
   PubMed Web of Science ®Google Scholar
• Ladouceur M , FermanianC, LupoglazoffJMet al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am. J. Cardiol., 99(3), 406–409 (2007).
   PubMed Web of Science ®Google Scholar
• Pyeritz RE , LoeysB. The 8th international research symposium on the Marfan Syndrome and related conditions. Am. J. Med. Genet. A., 158A(1), 42–49 (2012).
   PubMedGoogle Scholar
• Lacro RV , DietzHC, SleeperLAet al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N. Engl. J. Med., 371(22), 2061–2071 (2014).
   PubMed Web of Science ®Google Scholar
• van Thiel BS , VanDer Pluijm I, TeRiet L, EssersJ, DanserAHJ. The renin–angiotensin system and its involvement in vascular disease. Eur. J. Pharmacol., 763(Pt A), 3–14 (2015)
   PubMedGoogle Scholar
• Lindsay ME , DietzHC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature, 473(7347), 308–316 (2011).
   PubMed Web of Science ®Google Scholar
• Moltzer E , EssersJ, Van EschJHM, Roos-HesselinkJW, DanserAHJ. The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications. Pharmacol. Ther., 131(1), 50–60 (2011).
   PubMed Web of Science ®Google Scholar
• Inoue N , MuramatsuM, JinDet al. Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II-infused ApoE-deficient mice. J. Atheroscler. Thromb., 16(3), 164–171 (2009).
   PubMed Web of Science ®Google Scholar
• Habashi JP , DoyleJJ, HolmTMet al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science, 332(6027), 361–365 (2011).
   PubMed Web of Science ®Google Scholar
• Te Riet L , van DeelED, van ThielBSet al. AT1-receptor blockade, but not renin inhibition, reduces aneurysm growth and cardiac failure in fibulin-4 mice. J. Hypertens., 34(4), 654–665 (2016).
   PubMed Web of Science ®Google Scholar
• Huang J , YamashiroY, PapkeCLet al. Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Sci. Transl. Med., 5(183), 1–11 (2013).
   Web of Science ®Google Scholar
• Xiong F , ZhaoJ, ZengG, HuangB, YuanD, YangY. Inhibition of AAA in a rat model by treatment with ACEI perindopril. J. Surg. Res., 189(1), 166–173 (2014).
   PubMed Web of Science ®Google Scholar
• Liao S , MirallesM, KelleyBJ, CurciJA, BorhaniM, ThompsonRW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J. Vasc. Surg., 33(5), 1057–1064 (2001).
   PubMed Web of Science ®Google Scholar
• Thompson A , CooperJA, FabriciusM, HumphriesSE, AshtonHA, HafezH. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J. Vasc. Surg., 52(1), 55–61 (2010).
   PubMed Web of Science ®Google Scholar
• Yetman AT , BornemeierRA, McCrindleBW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am. J. Cardiol., 95(9), 1125–1127 (2005).
   PubMed Web of Science ®Google Scholar
• Brooke BS , HabashiJP, JudgeDP, PatelN, LoeysB, DietzHC. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N. Engl. J. Med., 358(26), 2787–2795 (2008).
   PubMed Web of Science ®Google Scholar
• Wang C , QianX, SunX, ChangQ. Angiotensin II increases matrix metalloproteinase 2 expression in human aortic smooth muscle cells via AT1R and ERK1/2. Exp. Biol. Med. (Maywood), 240(12), 1564–1571 (2015).
   PubMed Web of Science ®Google Scholar
• Bicknell CD , KiruG, FalaschettiEet al. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). Eur. Heart J., 37(42), 3213–3221 (2016).
   PubMed Web of Science ®Google Scholar